/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The BioHub - by Avetix
  2. Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences
Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences

The BioHub - by Avetix · Oct 6, 2026

ReAlta Life Sciences is advancing a dual-action peptide to treat newborn brain injury, targeting high unmet needs in ~400 US NICUs.

Interventional Neonatal Trials Must Anchor Experimental Dosing Directly to Standard Cooling Protocols

In acute neonatal conditions like hypoxic-ischemic encephalopathy, standard care dictates placing babies into therapeutic hypothermia blankets within neonatal ICUs for three days. Rather than disrupting established workflows, ReAlta designed its clinical dosing to begin within six to ten hours of birth, administering ten injections at eight-hour intervals during hypothermia before day-four MRI evaluations. This precise alignment preserves standard care while maximizing clinical trial operational feasibility.

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences thumbnail

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences

The BioHub - by Avetix·a month ago

Board-Level Diligence De-Risks Executive Transitions into High-Unmet-Need Biotech Startups

Moving into full-time C-suite roles at early-stage biotechs carries immense operational and clinical risk. Both Kia Motesharei and Howard Berman initially joined ReAlta Life Sciences at the board and chairman levels. This vantage point provided unfiltered access to preclinical findings, clinical safety data, intellectual property, and regulatory dynamics, allowing them to perform an exhaustive risk-reward assessment before taking operational helms as COO and CEO.

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences thumbnail

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences

The BioHub - by Avetix·a month ago

Concentrated Acute Point-of-Care Networks Greatly Simplify Biotech Commercial Footprints

Acute neonatal disorders do not require massive primary care sales organizations because patient treatment is heavily centralized. Kia Motesharei notes that the entire US market for hypoxic-ischemic encephalopathy is concentrated across approximately 400 neonatal intensive care units (NICUs). This highly localized setting allows an emerging biotech company to map out point-of-sale infrastructure and commercial launch teams with high efficiency years before final drug approval.

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences thumbnail

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences

The BioHub - by Avetix·a month ago

Viral Non-Inflammatory Peptide Sequences Can Simultaneously Inhibit Complement and Neutrophil Cascades

Most viruses trigger inflammatory responses, but the astrovirus produces non-inflammatory gastroenteritis. Howard Berman details how isolating a 15-amino-acid peptide from the astrovirus capsid protein yielded pectirazimod. The resulting therapeutic potently suppresses inflammation across two distinct mechanisms at once: binding extracellularly to block the C1 complement pathway while also inhibiting activated neutrophils and myeloperoxidase in acute conditions like HIE.

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences thumbnail

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences

The BioHub - by Avetix·a month ago

Early Brain MRI Scans Enable Accelerated Approval When Neonates Lack Measurable Functional Skills

Measuring clinical efficacy in newborns is difficult because they lack motor or cognitive skills at birth. Kia Motesharei explains that for hypoxic-ischemic encephalopathy (HIE), demonstrating reduced or eliminated brain injury on day-four MRIs offers a viable surrogate marker for accelerated FDA approval. Long-term functional motor and cognitive benchmarks can then be evaluated at two years of age for standard full approval.

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences thumbnail

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences

The BioHub - by Avetix·a month ago

Developing First-Ever Indications Requires Co-Creating Regulatory Roadmaps Alongside Clinical Execution

When pioneering a therapy in a disease without precedent approvals, regulatory agencies operate on draft guidance. Drawing on his past work at Madrigal developing the first MASH therapy, Kia Motesharei emphasizes that sponsors must proactively engage regulators years ahead of commercialization. High unmet medical needs in rare indications grant agencies regulatory flexibility, allowing companies to collaborate with the FDA to define acceptable surrogate endpoints and approval pathways.

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences thumbnail

Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences

The BioHub - by Avetix·a month ago